Enveric Biosciences – Clinical Development of Cannabinoids and Psychedelics

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Share on email
Email



Enveric Biosciences recently announced that it has signed a definitive agreement to acquire MagicMed Industries, a pharmaceutical drug discovery and development platform focused on new-generation psychedelic molecular compounds and derivatives.With this acquisition, Enveric will expand and complement its pipeline of naturally occurring cannabinoid compounds with a robust portfolio of psychedelic-derived molecules. Enveric aims to move into the clinic with novel cannabinoid and psychedelic-derived therapies to improve standard of care and serve unmet needs across multiple indications including oncology and CNS, such as PTSD. Upon closing, Dr. Joseph Tucker will be appointed Enveric Biosciences CEO and David Johnson as Executive Chairman.
#EnvericBiosciences #Cannabinoids #Psychedelics

View original source video by clicking here

On Key

Related Posts

Charles Urquhart, . Psychedelics & Cannabinoid Therapeutics: What Does the Future Hold?

Watch the full version of this talk: https://www.conferencecast.tv/talk-33555-psychedelics-cannabinoid-therapeutics-what-does-the-future-hold?utm_campaign=33555&utm_source=youtube&utm_content=talk CBD Expo SOUTH 2020, December 11 – 12, 2020, Houston See more about the event: https://www.conferencecast.tv/event-1649-cbd-expo-south-2020?utm_campaign=33555&utm_source=youtube&utm_content=conf Psychedelics